ERAS-601

Phase 2Small molecule

ERAS-601 is one of 44 small molecule programs targeting Advanced or Metastatic Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid TumorsActive, not recruiting

ChordomaRecruiting

Advanced or Metastatic Solid TumorsPreclinical

Active, not recruiting

ChordomaPhase 2

Recruiting

Competition

Competitive Landscape

80 competitors in Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

20 2

Opdivo

Bristol-Myers Squibb

Phase 2

4 3

Gemzar

Johnson & Johnson

Phase 2

4 4

Taxol

Teva

Phase 2

4 5

Eloxatin

Teva

Phase 2

2 6

Avastin

Roche

Phase 2

1 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

7 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 9

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

1 10

Platinum

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Chordoma

NCT06957327

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors2 trials

An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors

Completed·EErasca, Inc.·Phase 1·NCT04670679·90 enrolled

A Phase 1b/2, Open-label, Multi-center Study of ERAS-007 (ERK Inhibitor) Administered as Monotherapy or in Combination With ERAS-601 (SHP2 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1)

Completed·EErasca, Inc.·Preclinical·NCT04866134·85 enrolled

Advanced NSCLC1 trial

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Completed·EErasca, Inc.·Phase 1·NCT04959981·24 enrolled

Chordoma1 trial

A Study of ERAS-601 in People With Chordoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT06957327·46 enrolled

Hematologic Malignancies1 trial

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Withdrawn·EErasca, Inc.·Phase 1/2·NCT05279859

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ERAS-601. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ERAS-601 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ERAS-601. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Erasca, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EErasca, Inc.

ERAS-601

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Advanced or Metastatic Solid Tumors2 trials

Advanced NSCLC1 trial

Chordoma1 trial

Hematologic Malignancies1 trial

References

Drug Info

Quick Facts

Related News